Title page.

Title.

Correlation of post-vaccination fever with specific antibody response to SARS-CoV-2

BNT162b2 booster and no significant influence of antipyretic medication

Author names and affiliations.

Naoki Tani¹⁾, Hideyuki Ikematsu²⁾, Takeyuki Goto¹⁾, Kei Gondo³⁾, Takeru Inoue¹⁾, Yuki

Yanagihara⁴⁾, Yasuo Kurata⁴⁾, Ryo Oishi⁵⁾, Junya Minami⁵⁾, Kyoko Onozawa⁵⁾, Sukehisa

Nagano⁶⁾, Hiroyuki Kuwano⁷⁾, Koichi Akashi¹⁾, Nobuyuki Shimono⁸⁾ and Yong Chong¹⁾

1) Medicine and Biosystemic Science, Kyushu University Graduate School of Medical

Sciences, Fukuoka, Japan.

2) Ricerca Clinica Co., Fukuoka, Japan.

3) Clinical Laboratory, Fukuoka City Hospital, Fukuoka, Japan

- 4) Pharmacy, Fukuoka City Hospital, Fukuoka, Japan.
- 5) Department of Infectious Diseases, Fukuoka City Hospital, Fukuoka, Japan.
- 6) Department of Neurology, Fukuoka City Hospital, Fukuoka, Japan.
- 7) Fukuoka City Hospital, Fukuoka, Japan.

8) Center for the Study of Global Infection, Kyushu University Hospital, Fukuoka, Japan.

Keywords

Antipyretic; SARS-CoV-2; Vaccine; Antibody; Reactogenicity;

Running title.

Correlation of fever with IgG titers

Corresponding author.

Yong Chong, M.D., Ph.D.

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical

Sciences, 3-1-1 Maidashi, Higashi-ward, Fukuoka 812-8582, Japan.

Tel.: +81-92-642-5229; Fax: +81-92-642-5247

E-mail: jeong.yong.342@m.kyushu-u.ac.jp

Alternate corresponding author.

Naoki Tani, M.D.

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical

Sciences, 3-1-1 Maidashi, Higashi-ward, Fukuoka 812-8582, Japan.

Tel.: +81-92-642-5229; Fax: +81-92-642-5247

E-mail: tani.kyushu.univ@gmail.com

40-word summary

Spike-specific IgG titers after a BNT162b2 booster were measured for healthcare workers.

Adverse reactions and self-medicated antipyretics were reported. Post-booster vaccination

fever was correlated with the specific IgG titers. Antipyretics used for adverse reactions did

not suppress specific IgG induction.

Abstract

Background: A SARS-CoV-2 mRNA vaccine booster elicits sufficient antibody responses that protect against COVID-19, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use.

Methods: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 two-dose primary series. Spike-specific IgG titers were measured for SARS-CoV-2-naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and selfmedicated antipyretics were reported daily for seven days following vaccination through a web-based self-reporting diary.

Results: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (beta=0.305, p<0.001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk: 3.97 [95% confidence interval: 2.48-6.35]); however, the IgG titers after the booster dose were not affected by fever after the second dose. There were no significant

differences in the IgG titers by the use, type, or dosage of antipyretic medication.

Conclusions:

These results suggest an independent correlation between mRNA vaccine-induced specific

IgG levels and post-booster vaccination fever, without any significant influence of fever after

the primary series. Antipyretic medications for adverse reactions would not interfere with the

elevation of specific IgG titers.

1. Introduction

Administration of an mRNA coronavirus disease 2019 (COVID-19) vaccine has shown high vaccine efficacy, substantially reducing the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the development of severe or critical disease [1– 4]. These efficacy data are consistent with evidence from immunogenicity studies that show robust specific antibody responses to the mRNA COVID-19 vaccines [5,6]. It is notable that the specific IgG and neutralization titers of vaccinees who received an mRNA COVID-19 vaccine exceeded those of recovered COVID-19 patients [7,8]. On the other hand, the reactogenicity of mRNA COVID-19 vaccines is known to be relatively high, and fever is a common adverse reaction. Around 15% of vaccinees had fever after the second or third dose of an mRNA COVID-19 vaccine [1,9,10], while only 1-2% did so after influenza or pneumococcal vaccination [11,12]. The possible relation between adverse reactions, including fever, and the antibody responses to mRNA COVID-19 vaccines remains to be fully elucidated. Antipyretic or pain medications (antipyretics) are often used to mitigate the frequent adverse events. Public health authorities allow the therapeutic use of antipyretics [13,14], but data for the possible influence of their use on the antibody responses to COVID-19 vaccines are insufficient.

We previously investigated the influence of adverse reactions and the use of antipyretics on the specific antibody responses to the two-dose primary series of BNT162b2 vaccine (Pfizer, Inc., and BioNTech). A positive correlation of degree of fever after the second dose and little interference from the antipyretic medications on the antibody titers were shown [15]. In the present study of the same cohort, we prospectively investigated the influence of adverse reactions, which were evaluated using a standardized assessment tool, and the use of antipyretics on the specific antibody responses to a booster dose of BNT162b2 vaccine. In addition, using the data of the participants for whom information on both the second and booster doses were available, we also evaluated whether the specific antibody titers after the booster dose are affected by fever after the second dose.

2. Participants and methods

2.1. Participants

Eligible participants were healthcare workers who received three 30µg doses of BNT162b2 at Fukuoka City Hospital in Japan. The primary two-dose vaccine series with a 21-day interval was administered between March and June 2021, and the booster dose was given between December 2021 and January 2022. Included in the analysis were vaccinees who had serum sampling done 14 days or more after the booster dose and who completely responded to questionnaires about their background and solicited adverse reactions. The exclusion criteria were: 1) previously diagnosed with COVID-19 by laboratory tests, 2) positive results for antibodies targeting the viral nucleocapsid protein (IgG(N)), 3) the use of an antipyretic within 24 hours before the booster dose, and 4) receiving immunosuppressive therapy.

All participants provided written informed consent before undergoing any of the study procedures. The study was approved by the ethics review board of Fukuoka City Hospital (approval number 228) and registered in the University Hospital Medical Information Network-Clinical Trials Registry (registration no. UMIN000046246).

2.2. Demographic characteristics, reactogenicity, and antipyretic medications

Participant background information was collected by a web-based questionnaire. Local and systemic adverse reactions were reported daily for seven days after the booster dose through a web-based self-reporting diary. The solicited data were as follows: 1) local reactions (pain at the infection site, redness, and swelling), and 2) systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, muscle pain, joint pain, and lymphadenopathy). Axillary body temperature was measured twice daily, morning and night, and whenever the participant felt feverish. The highest body temperature during the seven days was used in the analysis. All solicited reactions except lymphadenopathy were recorded based on standardized assessment scales developed by the US Food and Drug Administration guidelines [16].

Lymphadenopathy was evaluated for its presence or absence. The use of an antipyretic was left up to the participant. Information on the self-medicated antipyretics, including name, dosage, timing, and reason for use, was collected daily with the solicited adverse reactions for the seven days after the booster dose.

Previously collected data on the IgG(S-RBD) titers and adverse reactions to the second dose were used in the present study. The major differences in the method of data collection were that in the earlier studies the adverse reaction information was collected for five days, not seven, after each of the doses and that we had used an originally defined

subjective scaling method, except for fever. The detailed methods are shown in our previous study [15].

2.3. Serological testing

Serum samples were collected twice, before and after the booster dose. The interval between the booster dose and the sampling after vaccination was scheduled at approximately one month to match it with the interval between the second dose and the sampling [15]. The quantitative levels of IgG antibodies for the receptor binding domain of the S1 subunit of the viral spike protein (IgG(S-RBD)) and IgG(N) were measured using the SARS-CoV-2 IgG II assay and SARS-CoV-2 IgG assay, respectively (Abbott Laboratories Co., Ltd., Park, IL, USA). Signal-to-cutoff values of \geq 1.4 AU/mL were applied for IgG(N) positivity [17].

2.4. Statistical analysis

The IgG(S-RBD) titers were log-transformed for analysis. The median, interquartile range (IQR), geometric mean titer (GMT), fold change, 95% confidence interval (CI), and relative risk (RR) were calculated. Between-group differences were calculated with Student's t test, ANOVA, or post hoc Dunnett's test in line with suitability. Correlation coefficients were

calculated using Spearman's correlation coefficient. Multivariate linear regression models

with a stepwise selection procedure were established. The level of significance was set at

<5%, two-sided. All analyses were performed using the SAS software package, release 9.4

(SAS Institute, Cary, NC).

3. Results

3.1. Demographic characteristics

Among 419 staff members who received the BNT162b2 booster, serum samples were collected from 346, and 316 satisfied the inclusion criteria. Of these, 13 were excluded due to a history of COVID-19 or IgG(N) \geq 1.4 AU/mL, 20 due to pre-vaccination use of antipyretics, and 2 due to having received immunosuppressive therapy, leaving the data of 281 participants available for analysis. Demographic and background information are summarized in Table 1. The median age was 41 years (IQR, 33-50), 72.6% were female, all were Japanese, and 77.2% had no coexisting conditions. The median interval between the second and booster doses was 262 days (IQR, 260-264, range, 219-288). Serum samplings before and after the booster dose were taken approximately eight months after the second dose (median, 247 days, IQR, 244-252) and one month after the booster dose (median, 32 days, IQR, 29-33), respectively.

3.2. IgG(S-RBD) titer and fold change by demographic characteristics
The booster dose increased the GMT of IgG(S-RBD) 29.4-fold (95% CI, 26.7-32.5), from
573 AU/mL (95% CI, 528-621) to 16,707 AU/mL (95% CI, 15,403-18,122). The IgG(S-

RBD) titers and fold changes according to demographic characteristics are shown in Table 1. In the analysis of the IgG(S-RBD) titers, sex and age showed no significant correlation (p=0.197 and p=0.645, respectively). In contrast, both were significantly correlated with the fold changes. The mean fold-change in males was higher than that in females (36.7-fold (95% CI, 31.1-43.3) vs 26.7-fold (95% CI, 24.4-29.3), p<0.001). Age showed a positive correlation with the fold changes (r=0.244, p<0.001). Comorbidities other than diabetes were not correlated. Diabetes had statistically significant correlations with both the IgG(S-RBD) titers and fold changes, but it was not further analyzed due to the small number of participants with diabetes.

3.3. IgG(S-RBD) titer and fold change by adverse reaction

The IgG(S-RBD) titers and fold changes after the booster dose by the solicited adverse reactions are shown in Table 2. None of the local reactions had a significant influence on the IgG(S-RBD) titers. Among the systemic reactions, fever showed a positive correlation with the IgG(S-RBD) titers (r=0.262, p<0.001). Fatigue (p=0.022), headache (p=0.024), chills (p=0.001), and lymphadenopathy (p<0.001) were also positively correlated. Neither local nor systemic adverse reactions significantly affected the fold changes in IgG(S-RBD) titers.

Factors that showed a p-value of <0.2, including sex, body mass index, smoking history, heart disease, fever, fatigue, headache, chills, vomiting, and lymphadenopathy, in the univariate analyses were incorporated in multivariate analysis. Among these variables, only fever (p<0.001, standardized regression coefficient beta 0.305 [95% CI, 0.193-0.417]) was extracted as being independently correlated with the IgG(S-RBD) titers (adjusted R² 0.090). A similar analysis for the fold change in IgG(S-RBD) titers extracted age (p<0.001, beta 0.248 [95% CI, 0.136-0.360]), male sex (p=0.001, beta 0.183 [95% CI, 0.071-0.294]), and fever (p=0.018, beta 0.136 [95% CI, 0.024-0.248]) as significant (adjusted R² 0.105).

3.4. Influence of antipyretic medications on IgG(S-RBD) titer and fold change The analyses of the influence of antipyretics on the IgG(S-RBD) titers and fold changes are shown in Table 3. In total, 119 (42.4%) participants used antipyretics during the seven days after the booster dose. None of the participants prophylactically used an antipyretic after the vaccination to prevent adverse events. The GMT of IgG(S-RBD) was comparable between the groups with and without antipyretic use (17,466 AU/mL (95% CI, 15,279-19,966) vs 16,170 AU/mL (95% CI, 14,601-17,906), p=0.357). Similarly, there was no significant difference in the mean fold-change between the two groups (29.4-fold (95% CI, 26.1-33.2) vs

28.9-fold (95% CI, 25.9-32.4), p=0.893). No significant influence of antipyretic use was found when stratified by fever grade, classified into <37.0 °C, 37.0-37.9 °C, and ≥38.0 °C. The most commonly used antipyretic combination was acetaminophen monotherapy (43/119, 36.1%), followed by loxoprofen monotherapy (35/119, 29.4%) and ibuprofen monotherapy (14/119, 11.8%). The IgG(S-RBD) titers and fold changes of the group with non-steroidal anti-inflammatory drugs (NSAIDs) such as loxoprofen and ibuprofen were comparable to those of acetaminophen. The IgG(S-RBD) titers by all combinations of antipyretics used are summarized in Table s1.

3.5. Association between the presence or absence of an adverse reaction after the second dose and the emergence of the same reaction after the booster dose

Using the data of 164 participants for whom information on both the second and booster doses were available, the probability of a solicited adverse reaction after the booster dose was investigated by the presence or absence of the corresponding reaction after the second dose (Table 4). The RR of all solicited adverse reactions were over 1.0. The presence of swelling at the infection site, fever of $38.0 \ge ^{\circ}$ C, headache, chills, muscle pain, and joint pain after the second dose showed a significant association with the emergence of the corresponding

reaction after the booster dose. The RR was the highest for the fever, at 3.97 (95% CI, 2.48-6.35).

3.6. IgG(S-RBD) titer by the presence of fever after the second and booster doses The 164 participants were divided into four groups by the presence or absence of fever of \geq 38.0°C after each dose. The IgG(S-RBD) titers of these four groups one month after the second dose, eight months after the second dose, and one month after the booster dose are shown in Table 5. The GMTs of IgG(S-RBD) one month after the second dose were higher for the groups with fever after the second dose than for those without. Eight months after the second dose, the differences among the groups were subtle, ranging from 537 to 796 AU/mL, without significant differences. The GMTs of IgG(S-RBD) one month after the booster dose were higher in the groups with fever after the booster dose, and they were comparable between the groups with and without fever after the second dose. A multivariate analysis incorporating fever after the second dose was additionally done. Fever after the booster dose was extracted as being significantly correlated with the IgG(S-RBD) titers after the booster dose (p=0.001, beta 0.246 [95% CI, 0.097-0.395]), but fever after the second dose was not.

4. Discussion

A booster dose of an mRNA COVID-19 vaccine induces a higher antibody titer than is produced by the primary two-dose series [18,19]. Our previous study showed that the IgG(S-RBD) titers after the second dose of the primary series were relatively low for male participants and the elderly [15], as shown in other studies [20,21]. In contrast, in the present study of the booster dose for the same cohort, male sex and age showed positive correlations with the fold change in IgG(S-RBD) titers, reaching comparable levels in the IgG(S-RBD) titers by sex and age. Other studies have also shown that the specific IgG titers after the BNT162b2 booster were comparable for sex and age [22,23]. The mechanism for the difference in the immunogenicity of a BNT162b2 vaccine by sex and age between the second and booster doses is unclear, but the booster vaccination would drive antibody productions, especially in the populations with relatively weak responses to the primary series.

The relation between the emergence of vaccine-related adverse reactions and antibody induction by the primary series of mRNA COVID-19 vaccines has been reported. Studies that used scores based on the sum of the presence or a severity scale of solicited adverse reactions showed no significant correlation of adverse reactions with the spikespecific IgG titers [24–26]. On the other hand, when each reaction was separately analyzed,

the presence of fever after the second dose was shown to be correlated with high IgG titers [27]. In the study, fever was used in the analysis by its presence or absence, not degree. We previously showed that degree of fever after the second dose was correlated with the IgG(S-RBD) titers by a multivariate analysis [15]. In the present study, the degree of fever after the booster dose, which was defined by the highest body temperature after the vaccination, was again shown to have a significant correlation with the IgG(S-RBD) titers. The mechanism of how fever after SARS-CoV-2 mRNA vaccination is linked to the antibody production remains unclear. Elucidating the mechanism will lead to a better understand of the sufficient antibody induction mechanism of mRNA COVID-19 vaccines.

The possibility of a relation between post-vaccination fever and the SARS-CoV-2 specific antibody titers has created concern that antipyretics, which can suppress fever, may have a negative influence on antibody responses to SARS-CoV-2 vaccination. To date, few studies have been done to determine the influence of antipyretics on the immunogenicity of COVID-19 vaccines. We previously showed that therapeutic use of antipyretics did not interfere with the antibody responses to the primary BNT162b2 series [15]. In the present study for the BNT162b2 booster, no influence of antipyretic use on the IgG(S-RBD) titers was observed again. Although several in vitro laboratory studies have demonstrated that

NSAIDs inhibit several pathways leading to antibody responses [28–30], the IgG(S-RBD) titers of the group with NSAIDs were comparable to those of the group with acetaminophen. The present study was not designed to evaluate the influence by the type of antipyretics, but it is suggested that neither acetaminophen nor NSAIDs would interfere with the elevation of IgG(S-RBD) titers. Antipyretics may also be used prophylactically. One study of a COVID-19 adenoviral vector vaccine reported that prophylactic acetaminophen use reduced many adverse reactions without interfering with antibody responses [31]. There are no studies on the influence of prophylactic use of antipyretics on antibody responses to mRNA COVID-19 vaccines. Taken together, our results indicate that the therapeutic use of antipyretics, regardless of the type, acetaminophen or NSAIDs, would be helpful for alleviating adverse reactions, including fever, without interfering with antibody responses to SARS-CoV-2 mRNA vaccination.

It would be of great interest for physicians whether the presence of an adverse reaction after the two-dose primary series is useful to predict the emergence of the corresponding reaction after the booster dose. In the present study, the presence of swelling as a local reaction and several systemic reactions including fever after the second dose was associated with the emergence of the corresponding reactions after the booster dose. Fever

after the second dose showed the highest RR of 3.97. Of interest, fever after the booster dose was independently correlated with the IgG(S-RBD) titers after the booster dose, irrespective of fever after the second dose. Thus, the participants with fever after the second dose may be more likely to have fever after the booster dose, but fever after the second dose would not affect the antibody responses to the booster dose. To our knowledge, no investigations of the correlation between post-vaccination fever and specific IgG levels have been done in the same cohort throughout the primary and booster vaccinations. These findings impress a potential linking of post-vaccination fever with the antibody production induced by mRNA COVID-19 vaccines.

This study has some limitations that should be acknowledged. First, it is a singlecenter observational study with a relatively small sample size of 281 participants. Additionally, the population was relatively young and predominantly female. Second, the data collection methods for the solicited adverse reactions were slightly different between the second and booster doses. The data collection period for adverse reactions was seven days after vaccination for the booster dose, while it was five days for the second dose. However, most common adverse reactions have been known to occur within a few days after vaccination [32], thus, the difference would have little impact on our findings. Finally, the type, dosage, and timing of antipyretic usage were chosen by each participant and are thus arbitrary. Randomized, large scale, controlled studies will be necessary to clarify the influence of antipyretics on the immunogenicity outcomes of COVID-19 vaccines, but we feel that our real-world data from healthcare workers with self-medicated antipyretics is informative.

In conclusion, a booster dose of BNT162b2 vaccine can restore waning immunity and significantly increase the antibody titers, especially in males and the elderly who had relatively low antibody responses to the primary two-dose series. Post-booster vaccination fever could be independently correlated with mRNA vaccine-induced specific IgG levels, without any significant influence of fever after the primary series. Antipyretic medications would be helpful to alleviate suffering from adverse reactions, without suppressing the specific IgG responses induced by a BNT162b2 vaccine booster.

Potential conflicts of interest.

The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form

for Disclosure of Potential Conflicts of Interest.

Funding.

This work was supported by our own resources.

Acknowledgments

We thank all of the staff members of Fukuoka City Hospital for their support for sample

collection and data reduction.

References

- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383:2603–2615. Available at: https://doi.org/10.1056/NEJMoa2034577.
- 2. Baden LR, el Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273

SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384:403-416. Available at:

https://doi.org/10.1056/NEJMoa2035389.

- Moreira EDJ, Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022;386(20):1910-1921. Available at: https://doi:10.1056/NEJMoa2200674.
- Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2
 Booster across Age Groups. N Engl J Med. 2021; 385:2421–2430. Available at: https:// doi:10.1056/NEJMoa2115926.
- Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2
 Vaccine Dose 3. N Engl J Med. 2021; 385:1627–1629. Available at:

https://doi.org/10.1056/NEJMc2113468.

- Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022; 28:477–480. Available at: https://doi.org/10.1038/s41591-021-01676-0.
- Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021; 12:3991. Available at: https://doi:10.1038/s41467-021-24285-4.
- 8. Yu Y, Esposito D, Kang Z, et al. mRNA vaccine-induced antibodies more effective

than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Sci Rep. **2022**; 12:2628. Available at: https://doi:10.1038/s41598-022-06629-2.

- Paran Y, Saiag E, Spitzer A, et al. Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers. Open Forum Infect Dis.
 2022; 9:ofab656. Available at: https://doi.org/10.1093/ofid/ofab656.
- Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2
 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385:1761–1773.
 Available at: https://doi.org/10.1056/NEJMoa2110345.
- Pillsbury AJ, Glover C, Jacoby P, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018; 8:e023263. Available at: https://doi:10.1136/bmjopen-2018-023263.
- Pneumovax 23 (pneumococcal vaccine polyvalent) sterile, liquid vaccine for
 intramuscular or subcutaneous injection, prescribing information.
 http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf.
 Accessed on May 3, 2022.
- 13. Possible Side Effects After Getting a COVID-19 Vaccine. Available at:

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html. Accessed on May 3, 2022.

- Coronavirus (COVID-19) vaccines side effects and safety. Available at: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/safetyand-side-effects/. Accessed on May 3, 2022.
- Tani N, Chong Y, Kurata Y, et al. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. Vaccine.
 2022; 40:2062–2067. Available at: https//doi:10.1016/j.vaccine.2022.02.025.
- 16. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Available at: https://www.fda.gov/media/73679/download. Accessed on May 3, 2022.
- Madhusudhanan N, Lenin M, Ellen A, et al. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. J Clin Microbiol. 2021; 59:e00388-21. Available at: https://doi.org/10.1128/JCM.00388-21
- Busà R, Sorrentino MC, Russelli G, et al. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech

mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.

Front Immunol. 2022; 13:856657. Available at:

https://www.frontiersin.org/article/10.3389/fimmu.2022.856657.

19. Romero-Ibarguengoitia ME, Rivera-Salinas D, Hernández-Ruíz YG, et al. Effect of the

third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody

titers in healthcare personnel. PLoS One. 2022; 17:e0263942-. Available at:

https://doi.org/10.1371/journal.pone.0263942.

- Debes AK, Xiao S, Colantuoni E, et al. Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers. JAMA Intern Med. 2021; 181(12):1660-1662. Available at: https://doi:10.1001/jamainternmed.2021.4580.
- Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis.
 2021;73(11):2065-2072. Available at: https://doi:10.1093/cid/ciab381.
- Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
 JAMA 2021; 326:2203–2204. Available at: https://doi:10.1001/jama.2021.19885.

- 23. Lustig Y, Gonen T, Meltzer L, et al. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nat Immunol. 2022;
 10.1038/s41590-022-01212-3. Available at: https://doi.org/10.1038/s41590-022-01212-3.
- Müller L, Andrée M, Moskorz W, et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis.
 2021; 73:2065–2072. Available at: https://doi.org/10.1093/cid/ciab381.
- 25. Coggins SA, Laing ED, Olsen CH, et al. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infect Dis. 2022; 9:ofab575. Available at: https://doi.org/10.1093/ofid/ofab575.
- 26. Takeuchi M, Higa Y, Esaki A, Nabeshima Y, Nakazono A. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects? PLoS One. 2021; 16(9):e0257668. Available at: https://doi:10.1371/journal.pone.0257668.
- 27. Kanizsai A, Molnar T, Varnai R, et al. Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months

Follow-Up. Vaccines (Basel) 2022; 10:447. Available at:

https://pubmed.ncbi.nlm.nih.gov/35335080.

- Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother. 2016; 12:2391–2402. Available at: https://doi:10.1080/21645515.2016.1183077.
- 29. Ryan EP, Pollock SJ, Murant TI, Bernstein SH, Felgar RE, Phipps RP. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol. 2005; 174:2619–2626. Available at: https://doi:10.4049/jimmunol.174.5.2619.
- Purssell E. Cyclooxygenase inhibitors inhibit antibody response through interference with MAPK/ERK pathways and BLIMP-1 inhibition. Med Hypotheses. 2014;
 83:372–377. Available at: https//doi:10.1016/j.mehy.2014.06.015.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1
 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial. Lancet. 2020; 396:467–478. Available at:
 https://doi:10.1016/S0140-6736(20)31604-4.
- 32. Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the

initial 6 months of the US COVID-19 vaccination programme: an observational study

of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect

Dis. 2022; 22(6):802-812. Available at: https://doi:10.1016/S1473-3099(22)00054-8.

				IgG(S-RBD) titers before d	lose 3	IgG(S-RBD) titers after do	se 3	Change in titers after dose 3	
			No. (%)	GMT (95% CI), AU/mL	p-value	GMT (95% CI), AU/mL	p-value	Fold change, mean (95% CI)	p-value
All eligible participants			281	573 (528-621)		16,707 (15,403-18,122)		29.4 (26.7-32.5)	
Sex	Female		204 (72.6)	602 (546-665)	0.047	16,110 (14,743-17,604)	0.197	26.7 (24.4-29.3)	< 0.001
	Male		77 (27.4)	502 (436-577)		18,395 (15,325-22,085)		36.7 (31.1-43.3)	
Age	Absolute value, median (IQR), y		41 (33-50)	r=-0.215 ^a	< 0.001	r=0.009 ^a	0.877	r=0.231ª	< 0.001
	<40 years		127 (45.2)	648 (582-723)	0.014	16,970 (15,199-18,948)	0.509	26.2 (23.4-29.3)	0.006
	40-54 years		118 (42.0)	534 (472-603)		15,937 (14,055-18,072)		29.9 (26.2-34.0)	
	55≤ years		36 (12.8)	468 (345-634)		18,453 (13,623-24,995)		39.5 (30.7-50.7)	
Smoking	Never		234 (83.3)	602 (549-659)	0.030	17,249 (15,747-18,894)	0.134	28.7 (26.2-31.4)	0.473
	Ex-smoker		26 (9.3)	457 (385-543)		15,627 (12,922-18,899)		34.2 (27.8-42.1)	
	Current smoker		21 (7.5)	441 (321-605)		12,713 (9,214-17,540)		28.8 (21.3-39.1)	
Alcohol	None		113 (40.2)	598 (523-684)	0.493	17,781 (15,604-20,261)	0.465	29.7 (26.4-33.4)	0.698
	Sometimes		136 (48.4)	569 (510-634)		16.048 (14,358-17,937)		28.2 (25.0-31.8)	
	Almost everyday		32 (11.4)	508 (378-682)		15,907 (11,890-21,282)		31.3 (23.0-42.5)	
Body Mass Index	Absolute value, median (IQR), kg/m2	!	21.2 (19.7-23.3)	r=-0.032 ^a	0.599	r=0.091 ^a	0.130	r=0.137 ^a	0.022
	<18.5		26 (9.3)	531 (373-758)	0.417	15,055 (11,162-20,307)	0.545	27.2 (20.7-35.7)	0.079
	18.5-24.9		220 (78.6)	589 (539-645)		16,666 (15,268-18,192)		28.3 (25.8-31.0)	
	≥25.0		34 (12.1)	506 (408-682)		18,332 (15,695-24,540)		39.9 (32.2-44.5)	
Job Category	Nurse		140 (49.8)	575 (516-641)	0.483	15,704 (14,270-17,283)	0.488	27.3 (24.7-31.2)	0.061
	Clerk		40 (14.2)	648 (507-828)		15.731 (12,771-19,378)		24.3 (18.8-31.3)	
	Doctor		30 (10.7)	467 (362-602)		17,364 (12,091-24,936)		37.2 (27.3-50.7)	
	Radiologist		13 (4.6)	605 (438-837)		19,694 (12,239-31,690)		32.5 (17.7-59.8)	
	Pharmacist		12 (4.3)	652 (389-1,093)		19,696 (14,270-17,283)		30.2 (18.3-49.9)	
	Other		46 (16.4)	555 (443-694)		18,953 (15,130-23,742)		34.2 (28.4-41.1)	
Comorbidities	Allergic rhinitis	Yes	43 (15.3)	537 (448-645)	0.508	14,801 (11,989-18,277)	0.213	27.6 (23.2-32.7)	0.563
		No	238 (84.7)	580 (530-635)		16,963 (15,513-18,548)		29.4 (26.7-32.5)	
	Dislipidemia	Yes	17 (6.1)	656 (464-929)	0.405	20,333 (12,526-33,007)	0.381	31.0 (21.7-44.3)	0.710
		No	264 (94.0)	568 (522-618)		16,497 (15,205-17,898)		29.0 (26.7-31.6)	
	Hypertension	Yes	14 (5.0)	455 (262-790)	0.364	12,314 (6,393-23,719)	0.313	27.1 (18.0-40.7)	0.683
		No	267 (95.0)	580 (535-629)		16,975 (15,678-18,382)		29.3 (26.9-31.8)	
	Asthma	Yes	5 (1.8)	798 (470-1,352)	0.281	21,154 (11,389-39,292)	0.442	26.5 (15.4-45.8)	0.759
		No	276 (98.2)	570 (525-618)		16,634 (15,321-18,063)		29.2 (26.9-31.7)	
	Diabetes	Yes	3 (1.1)	439 (96-2,004)	0.504	41,850 (14,723-118,987)	0.021	95.3 (56.1-162.0)	0.003
		No	278 (98.9)	575 (529-624)		16,542 (15,251-17,943)		28.8 (26.5-31.2)	
	Heart disease	Yes	3 (1.1)	539 (324-894)	0.876	33,411 (3,446-323,966)	0.081	62.0 (6.1-632.8)	0.058
		No	278 (98.9)	573 (528-622)		16,581 (15,290-17,985)		28.9 (26.7-31.4)	
	Malignancy	Yes	3 (1.1)	460 (45-4,648)	0.581	19,838 (1,219-322,849)	0.666	43.1 (3.7-497.3)	0.327
		No	278 (98.9)	574 (529-623)		16,676 (15,374-18,088)		29.0 (26.8-31.5)	
	Chronic kidney disease	Yes	1 (0.4)	626 (N/A)	N/A	32,300 (N/A)	N/A	51.6 (N/A)	N/A
		No	280 (99.4)	573 (528-621)		16,669 (15,364-18,080)		29.1 (26.8-31.6)	

Table 1: Demographic characteristics, IgG(S-RBD) titer, and fold change.

Abbreviations: GMT, geometric mean titer; CI, confidence interval; IQR, interquartile range; N/A, not available.

a: r values refer to the Spearman's correlation coefficient.

		No. (%)	GMT (95% CI), AU/mL	p-value	Fold change, mean (95% CI)	p-value
Local reactions						
Pain at injection site	No	3 (1.1)	14,818 (4,032-54,450)	0.763	23.9 (10.9-52.4)	0.618
	Yes	278 (98.9)	16,730 (15,413-18,155)		29.2 (26.9-31.7)	
Redness	No	185 (65.8)	16,761 (15,198-18,484)	0.915	28.9 (26.2-31.9)	0.734
	Yes	96 (34.2)	16,604 (14,328-19,244)		29.7 (25.7-34.4)	
Swelling	No	148 (52.7)	16,707 (14,866-18,772)	0.998	30.5 (27.4-33.8)	0.269
	Yes	133 (47.3)	16,707 (14,907-18,728)		27.8 (24.5-31.6)	
systemic reactions						
Fever	Absolute value	281 (100)	r=0.262 ^a	< 0.001	r=0.082 ^a	0.170
	<37.0°C	114 (40.6)	14,011 (12,431-15,793)	< 0.001	26.9 (23.7-30.5)	0.100
	37.0-37.9°C	97 (34.5)	16,302 (14,174-18,750)		28.8 (25.3-32.9)	
	≥38.0°C	64 (24.9)	23,020 (19,670-26,941)		33.7 (28.1-40.5)	
Fatigue	No	42 (15.0)	13,329 (10,713-16,581)	0.022	26.2 (20.8-32.9)	0.278
	Yes	239 (85.1)	17,382 (15,933-18,967)		29.7 (27.2-32.4)	
Headache	No	94 (33.5)	14,652 (12,885-16,661)	0.024	29.3 (25.6-33.5)	0.947
	Yes	187 (66.6)	17,848 (16,099-19,783)		29.1 (26.3-32.3)	
Chills	No	135 (48.0)	14,534 (13,077-16,151)	0.001	27.3 (24.3-30.7)	0.126
	Yes	146 (52.0)	19,006 (16,862-21,419)		31.0 (27.6-34.8)	
Vomiting	No	272 (96.8)	16,512 (15,198-17,943)	0.121	29.1 (26.7-31.6)	0.721
	Yes	9 (3.2)	23,752 (16,021-35,221)		31.6 (22.5-44.5)	
Diarrhea	No	246 (87.5)	16,811 (15,385-18,365)	0.693	29.3 (26.8-32.0)	0.812
	Yes	35 (12.5)	15,999 (13,005-19,683)		28.4 (23.6-34.2)	
Muscle pain	No	40 (14.2)	17,434 (14,142-21,493)	0.674	28.9 (22.2-37.7)	0.944
	Yes	241 (85.8)	16,588 (15,181-18,126)		29.2 (26.8-31.8)	
Joint pain	No	128 (45.6)	16,044 (14,315-17,980)	0.370	27.9 (24.6-31.6)	0.335
	Yes	153 (54.5)	17,282 (15,396-19,404)		30.2 (27.1-33.7)	
Lymphadenopathy	No	194 (69.0)	15,332 (13,845-16,975)	< 0.001	29.1 (26.1-32.4)	0.956
	Yes	87 (31.0)	20,234 (17,857-22,935)		29.2 (26.2-32.7)	

Table 2: Influence of adverse reaction variables on IgG(S-RBD) titer.

Abbreviations: GMT, geometric mean titer; CI, confidence interval; IQR, interquartile range; N/A, not available.

a: r values refer to the Spearman's correlation coefficient.

				No. (%)	GMT (95% CI)	p-value	Fold change, mean (95% CI)	p-value
Use of antipyretic medications	All participants		No	162 (57.7)	16,170 (14,601-17,906)	0.357	28.9 (25.9-32.4)	0.893
			Yes	119 (42.4)	17,466 (15,279-19,966)		29.4 (26.1-33.2)	
	By fever grade	<37.0°C	No	85 (74.6)	14,217 (12,491-16,181)	0.681	27.8 (23.8-32.4)	0.400
			Yes	29 (25.4)	13,425 (10,006-18,009)		24.6 (19.9-30.3)	
		37.0-37.9°C	No	50 (51.6)	16,489 (13,602-19,985)	0.869	30.0 (24.7-36.4)	0.556
			Yes	47 (48.5)	16,106 (13,041-19,893)		27.7 (23.2-33.2)	
		≥38.0°C	No	27 (38.6)	23,388 (17,914-30,542)	0.874	31.0 (22.4-42.8)	0.465
			Yes	43 (61.4)	22,793 (18,612-27,906)		35.6 (28.3-44.6)	
Type of antipyretic		Only acetaminophen		43 (36.1)	17,132 (13,886-21,136)	Reference	26.3 (21.3-32.5)	Reference
		Only loxoprofen		35 (29.4)	14,820 (11,167-19,669)	0.744	25.4 (20.6-31.2)	0.991
		Only ibuprofen		14 (11.8)	20,306 (13,383-30,811)	0.815	41.2 (28.5-59.7)	0.068
		Other ^a		27 (22.7)	20,613 (15,651-27,149)	0.637	35.9 (28.3-45.6)	0.135
Total dosage of antipyretic during	g 7-days after vaccination ^b	Acetaminophen, median (mg, IQR)		900 (400-1,200)	r=0.072 ^b	0.648	r=0.247 ^b	0.111
		Loxoprofen, median (mg, IQR)		120 (60-180)	r=0.097 ^b	0.580	r=0.223 ^b	0.198
		Ibuprofen, median (mg, IQR)		200 (150-400)	r=-0.346 ^b	0.226	r=-0.201 ^b	0.491
Timing of antipyretic use		Antipyretic use on the day of vaccination	No	108 (90.8)	17,151 (14,856-19,797)	0.398	30.0 (26.4-34.1)	0.308
			Yes	11 (9.2)	20,903 (14,378-30,395)		24.3 (16.9-34.9)	

Table 3: Influence of antipyretics on IgG(S-RBD) titer and fold change after a booster dose.

Abbreviations: GMT, geometric mean titer; CI, confidence interval; IQR, interquartile range.

a: Including other type of antipyretics, combination drugs, or combination of several antipyretics.

b: r values refer to the Spearman's correlation coefficient.

		Corresponding	reactions after booster dose	Incidence of a corresponding reaction		
		Present	Absent	after booster dose, %	RR	95% CI
ocal reactions after do	ose 2					
Pain at injection site	Present	154	1	99.4	1.12	0.89-1.41
	Absent	8	1	88.9	Reference	Reference
Redness	Present	14	16	46.7	1.56	0.98-2.48
	Absent	40	94	29.9	Reference	Reference
Swelling	Present	45	23	66.2	1.93	1.39-2.66
	Absent	33	63	34.4	Reference	Reference
ystemic reactions afte	r dose 2					
Fever ≥38.0°C	Present	21	12	63.6	3.97	2.48-6.35
	Absent	21	110	16.0	Reference	Reference
Fatigue	Present	129	14	90.2	1.35	1.00-1.84
	Absent	14	7	66.7	Reference	Reference
Headache	Present	80	19	80.8	1.46	1.15-1.85
	Absent	36	29	55.4	Reference	Reference
Chills	Present	52	18	74.3	2.00	1.48-2.68
	Absent	35	59	37.2	Reference	Reference
Diarrhea	Present	3	17	15.0	1.14	0.37-3.50
	Absent	19	125	13.2	Reference	Reference
Muscle Pain	Present	85	6	93.4	1.22	1.06-1.40
	Absent	56	17	76.7	Reference	Reference
Joint Pain	Present	59	21	73.8	1.77	1.33-2.35
	Absent	35	49	41.7	Reference	Reference

Table 4: Probability of an adverse reaction after the booster dose according to the presence or absence of the same reaction after the second dose.

Abbreviations: RR, relative risk; CI, confidence interval.

Information on vomiting and lymphadenopathy after the second dose were not collected.

Fever ≥38.0°C after vaccination				1-month after dose 2		8-months after dose 2		1-month after dose 3	
(after dose 2/dose 3)	No. (%)	Female sex (%)	Age, median (IQR), y	GMT (95% CI), AU/mL	p-value	GMT (95% CI), AU/mL	p-value	GMT (95% CI), AU/mL	p-value
Absent/Absent	110 (67.1)	83 (75.5)	42.0 (33.0-49.0)	8,281 (7,305-9,386)	Reference	537 (474-607)	Reference	15,438 (13,665-17,441)	Reference
Present/Absent	12 (7.3)	9 (75.0)	33.5 (29.0-39.5)	12,026 (8,204-17,628)	0.169	796 (552-1,147)	0.144	14,644 (10,630-20,174)	0.990
Absent/Present	21 (12.8)	12 (57.1)	41.0 (46.0-51.0)	9,172 (6,717-12,524)	0.879	738 (515-1,058)	0.125	22,012 (16,555-29,270)	0.060
Present/Present	21 (12.8)	17 (81.0)	40.0 (28.0-44.0)	12,343 (9,562-15,932)	0.032	627 (481-817)	0.682	22,479 (16,575-30,487)	0.042

Abbreviations: IQR, interquartile range; GMT, geometric mean titer; CI, confidence interval.